Next Article in Journal
The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
Next Article in Special Issue
The Role of miRNAs in Virus-Mediated Oncogenesis
Previous Article in Journal
Expressing OsMPK4 Impairs Plant Growth but Enhances the Resistance of Rice to the Striped Stem Borer Chilo suppressalis
Previous Article in Special Issue
MicroRNA Expression Analysis of In Vitro Dedifferentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(4), 1183;

The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation

1,2,†,* , 2,3,4,†
Institute of General Pathology, Università Cattolica and Policlinico Gemelli, 00168 Rome, Italy
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy
Department of Internal Medicine and Medical Specialties, “La Sapienza” University, 00161 Rome, Italy
Regina Elena National Cancer Institute, 00144 Rome, Italy
RPPA Unit, Proteomics Area, Core Facilties, Istituto Superiore di Sanità, 00162 Rome, Italy
These authors contributed equally to this work.
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 13 March 2018 / Revised: 10 April 2018 / Accepted: 11 April 2018 / Published: 13 April 2018
(This article belongs to the Special Issue The Role of MicroRNAs in Human Diseases)
Full-Text   |   PDF [1039 KB, uploaded 3 May 2018]   |  


In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy. View Full-Text
Keywords: tumor-derived exosomes (TEXs); microRNAs; immune system; cancer tumor-derived exosomes (TEXs); microRNAs; immune system; cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Alfonsi, R.; Grassi, L.; Signore, M.; Bonci, D. The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation. Int. J. Mol. Sci. 2018, 19, 1183.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top